178 filings
Page 8 of 9
8-K
2ccguoib ylrf
25 Feb 15
Entry into a Material Definitive Agreement
12:00am
8-K
6p0jm6t
6 Feb 15
Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
12:00am
8-K
x2kk6ypyax45
30 Jan 15
Intercept Receives Breakthrough Therapy Designation from FDA for Obeticholic Acid for Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis
12:00am
8-K
od2 z77fi1a
12 Jan 15
Intercept Provides 2014 Year-End Update and Planned 2015 Milestones
12:00am
8-K
fr1xv uemabrvrijv
7 Nov 14
Intercept Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business Updates
12:00am
8-K
iuvmv6cvyiqb57zek0u1
12 Aug 14
Intercept Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Business Update
12:00am
8-K
elq42 kz0eh
22 Jul 14
Submission of Matters to a Vote of Security Holders
12:00am
8-K
xumupd 0sxn
28 May 14
Intercept Announces that FDA Grants Fast Track Designation to Obeticholic Acid for the Treatment of Patients with Primary Biliary Cirrhosis
12:00am
8-K
wnkrztxepyxjtfknj2f
22 May 14
Regulation FD Disclosure
12:00am
8-K
99h8zddvnpffco
7 May 14
Intercept Pharmaceuticals Reports First Quarter 2014 Financial Results
12:00am
8-K
daeh3cmy5onw q8
17 Apr 14
Departure of Directors or Certain Officers
12:00am
8-K
xs69 ierqq2k
4 Apr 14
Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
12:00am
8-K
hhkzi0dkkud mmphl
26 Mar 14
Other Events
12:00am
8-K
x7ragfrjq ih
17 Mar 14
Intercept Pharmaceuticals Announces 2013 Financial Results
12:00am
8-K
t3hqtcnjjc7n5o
17 Mar 14
Intercept Announces Positive Pivotal Phase 3 POISE Trial Results
12:00am
8-K
wg7wnlptgmpwggtruuh
18 Feb 14
Intercept Expands its Board of Directors with Appointments of Sanj K. Patel and Glenn Sblendorio
12:00am
8-K
o7amewzsq0
13 Jan 14
Regulation FD Disclosure
12:00am
8-K
dmunf79dfeiblf 62
10 Jan 14
Regulation FD Disclosure
12:00am
8-K/A
4yizj
2 Jan 14
Entry into a Material Definitive Agreement
12:00am
8-K
33bbg 9f5vcb
24 Dec 13
Other Events
12:00am